Eu Yan Sang’s net profit slipped 38% to $5.45m in Q3
Due to higher expenses.
Locally-listed traditional Chinese medicine manufacturer Eu Yan Sang reported that its net profit declined 38% year-on-year to $5.45m in the third quarter.
The decline was attributed to lower gross margin contribution and increased operating expenses. Gross margin for the quarter under review dipped 2.6% due mainly to the impact of sales mix and longer lead time to Chinese New Year.